Table 3. Univariate analyses of factors influencing survival.

	Disease-free survival			Overall survival
Factor	HR	95% CI	P -value	HR	95% CI	P -value
Age (years)	1.011	0.995–1.028	0.181	1.011	0.995–1.028	0.174
Gender	1.283	0.867–1.900	0.213	1.296	0.874–1.920	0.197
Year of treatment
1998–99	Reference group			Reference group
2000–01	1.701	0.722–4.006	0.224	1.791	0.651–4.655	0.269
2002–03	2.205	0.969–5.017	0.059	2.284	0.882–5.915	0.089
2004–05	1.977	0.880–4.445	0.099	2.034	0.794–5.213	0.139
2006–07	2.097	0.920–4.780	0.078	2.195	0.846–5.692	0.106
2008–09	1.593	0.644–3.938	0.313	1.704	0.612–4.746	0.308
2010–11	2.178	0.809–5.867	0.123	2.104	0.684–6.474	0.195
Path cell type	0.785	0.528–1.168	0.233	0.810	0.544–1.206	0.300
Any neo treatment	1.128	0.818–1.557	0.463	1.075	0.777–1.486	0.663
Treatment type
S	Reference group			Reference group
CS	1.194	0.847–1.682	0.312	1.144	0.809–1.617	0.446
CRTS	0.980	0.620–1.548	0.931	0.925	0.585–1.462	0.737
pT stage
CPR	Reference group			Reference group
T1	0.625	0.259–1.510	0.297	0.670	0.277–1.620	0.375
T2	1.760	0.797–3.889	0.162	1.875	0.849–4.143	0.120
T3	2.315	1.123–4.774	0.023	2.297	1.113–4.738	0.024
T4	3.959	1.367–11.467	0.011	3.869	1.335–11.208	0.013
pN stage	2.435	1.751–3.388	<0.0001	2.336	1.675–3.258	<0.0001
Tumour grade
Well	Reference group			Reference group
Moderate	3.024	1.314–6.960	0.009	2.830	1.229–6.516	0.015
Poor	4.157	1.801–9.595	0.001	4.035	1.746–9.328	0.001
CRM involvement	2.263	1.637–3.130	<0.0001	2.139	1.541–2.969	<0.0001
LV invasion	2.861	2.015–4.060	<0.0001	2.803	1.965–3.997	<0.0001
LNMC	1.115	1.074–1.158	<0.0001

Abbreviations: 95% CI=95% confidence interval; CPR=complete pathological response; CRM=circumferential resection margin; CRTS=neoadjuvant chemoradiotherapy; CS=neoadjuvant chemotherapy; HR=hazard ratio; LNMC=lymph node metastasis count; LV=lymphovascular; neo=neoadjuvant; path=pathological; S=surgery alone.